@tak1 RAC did a raise late 2021 for almost $30M, but it only really went to retail holders or existing RAC holders, because at the time, one of the Directors reckoned retail holders were better for the RAC register. More likely story is that institutional holders weren't interested. And some 12 moths later that Director left the business. doh.
As
@KingGnome notes above, our board, the management team and the scientific advisory board is made up of dozens of Professors and Doctors with a wide range of expertise. To suggest that these people are deliberating misleading shareholder is at best, ludicrous, at worst offensive and deceptive.
Mason makes some pretty sweeping statements after a google search, but this is the guy that thinks a recent report that outlines a $5B addressable market somehow vales RAC at $32 a share, failing to grasp the differences between addressable market opportunity, revenue and market cap.
Follow any of his so called "reasoned analysis" with a very large grain of salt. Or better still, disregard completely.
CF33 is out of the clinic, is now in patients and is doing what exactly what is expected. The other guys are still playing with mice.
